Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02137837
Title S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
Recruitment Terminated
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Southwest Oncology Group
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Fulvestrant

Anastrozole + Everolimus + Fulvestrant

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST